Compare ADMA Biologics Inc (ADMA) vs Procter & Gamble Co (PG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Procter & Gamble Co — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Procter & Gamble Co trades at $149.04 (market cap $355.69B). The key difference: Procter & Gamble Co is far larger — about 167× ADMA Biologics Inc's market cap, and Procter & Gamble Co pays a 2.79% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PG | |
|---|---|---|
Market Cap | $2.13B | $355.69B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $167.18 |
52-Week Low | $7.60 | $138.10 |
Enterprise Value | $2.20B | $381.17B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Procter & Gamble (PG) trades at $149.03, down 0.19% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company maintains robust fundamentals with $84.3B in revenue, 19.2% net income margin, and consistent earnings beats in recent quarters. Recent developments include a WNBA partnership and a $1.09 dividend declaration, while analyst consensus remains positive with a $159.88 price target.
PG offers stable growth with reliable dividend income but faces premium valuation concerns. Upside potential exists from supply chain efficiencies and brand strength, while risks include competitive pressures and economic sensitivity. Wall Street maintains a bullish stance with 56% buy ratings, though investors should monitor margin sustainability amid cost inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
